The HARBOR Study is currently enrolling individuals between 18 and 80 years of age who have been diagnosed with idiopathic pulmonary fibrosis (IPF).
Eligible participants must:
There are additional eligibility criteria, which the study team will discuss with participants.
Participants will be chosen at random to receive either the potential medicine or the placebo, which looks just like the potential medicine but does not contain active ingredients. Both the potential medicine and the placebo are tablets taken orally twice daily.
Participants will be asked to attend 12 visits to the study site and have two phone calls with the study team throughout the study. The total length of participation is approximately 64 weeks and consists of:
Throughout the study, the study doctor may perform a number of tests and procedures, including but not limited to: